UPF2 and neoplasm: These data are illustrated for UPF1 and UPF2 in Figure 4; tumor samples in which UPF1 and UPF2 expression are low (below the average) presented with variable rates of CD3ε positive-TILs while tumor samples in which UPF1 and UPF2 expression are high (above the average) were found to be nearly always characterized by a low CD3 count, making UPF1 and UPF2 possible markers of poor anti-tumor immunity in MSI primary CRCs.